Hengdi Pharmaceuticals: Wholly-owned subsidiary passed on-site inspection by the US FDA.

Hengdi Pharmaceuticals announced on the evening of May 16 that its wholly-owned subsidiary, Baik Pharmaceutical, underwent a routine on-site inspection by the US Food and Drug Administration (FDA) from March 10 to 14. Recently, Baik Pharmaceutical received the on-site inspection report issued by the FDA. According to the regulations of the US 21 CFR, the FDA confirmed that the inspection has ended and Baik Pharmaceutical passed the inspection. The inspection scope covered active pharmaceutical ingredients such as fluorouracil, milrinone, glasidone, and flumazenil.